Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Investigation|May 29, 2014
Four individually druggable MET hotspots mediate HGF-driven tumor progressionCristina Basilico, Anna Hultberg, Christophe Blanchetot, et al.
European Journal of Human Genetics : EJHG|April 14, 2005
Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage displayYanchao Huang, Peter Verheesen, Andreas Roussis, et al.
Nature Communications|October 14, 2022
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagementMaximilian Brinkhaus, Erwin Pannecoucke, Elvera J van der Kooi, et al.
The Journal of Clinical Investigation|July 25, 2018
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansPeter Ulrichts, Antonio Guglietta, Torsten Dreier, et al.
Communications Biology|December 16, 2025
TR-FRET between engineered nanobodies reveals the existence of endogenous CXCR4 oligomersJoyce Heuninck, Vladimir Bobkov, Claire M Grison, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Mabs|March 2, 2018
A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3Janna Bednenko, Rian Harriman, Lore Mariën, et al.
Biochemical Pharmacology|October 21, 2018
Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functionsVladimir Bobkov, Aurelien M Zarca, Anneleen Van Hout, et al.
Science Translational Medicine|April 24, 2015
Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivoJulia Cuende, Stéphanie Liénart, Olivier Dedobbeleer, et al.
Biochemical Pharmacology|October 21, 2018
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entryAnneleen Van Hout, Alex Klarenbeek, Vladimir Bobkov, et al.
Pageof 7